PepGen Announces Data From Its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 Demonstrates Mean Splicing Correction Of 46.5%; PGN-EDODM1 Showed High Tolerance;

Benzinga
Abrir em Benzinga